Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT02808975 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02808975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02808975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
July 18, 2016
Completion date
October 16, 2019
Enrollment
206 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)